UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

The Lancet (British edition), 2019-07, Vol.394 (10192), p.39-50

2019

Volltextzugriff (PDF)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.125-134

2022

Volltextzugriff (PDF)

Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

The American heart journal, 2021-12, Vol.242, p.160-160

2021

Volltextzugriff (PDF)

Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives

Diabetes therapy, 2020-08, Vol.11 (Suppl 2), p.33-48

2020

Volltextzugriff (PDF)

The Place of Sulfonylureas in Guidelines: Why Are There Differences?

Diabetes therapy, 2020-06, Vol.11 (Suppl 1), p.5-14

Amod, Aslam

2020

Volltextzugriff (PDF)

Introduction: Real-World Evidence in Type 2 Diabetes

Diabetes therapy, 2020-08, Vol.11 (Suppl 2), p.29-32

2020

Volltextzugriff (PDF)

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

Diabetes care, 2010-03, Vol.33 (3), p.605-607

2010

Volltextzugriff (PDF)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2012-07, Vol.17 (2), p.S1-S95

2012

Volltextzugriff (PDF)

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

The New England journal of medicine, 2021-12, Vol.385 (24), p.2252-2263

2021

Volltextzugriff (PDF)

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

The New England journal of medicine, 2020-12, Vol.383 (23), p.2219-2229

2020

Volltextzugriff (PDF)

Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management

Diabetologia, 2024-08

2024

Volltextzugriff (PDF)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Diabetes care, 2022-12, Vol.45 (12), p.2991-2998

2022

Volltextzugriff (PDF)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2012-04, Vol.17 (1), p.61-62

Amod, Aslam

2012

Volltextzugriff (PDF)

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

American journal of nephrology, 2019-11, Vol.50 (5), p.345-356

2019

Volltextzugriff (PDF)

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

American journal of nephrology, 2019-11, Vol.50 (5), p.333-344

2019

Volltextzugriff (PDF)

930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis

Annals of internal medicine, 2023-12, Vol.176 (12), p.1606

2023

Volltextzugriff (PDF)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Diabetes care, 2022-04, Vol.45 (4), p.888-e897

2022

Volltextzugriff (PDF)

406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

The Lancet (British edition), 2008-10, Vol.372 (9647), p.1385-1393

2008

Volltextzugriff (PDF)

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

The Lancet (British edition), 2008-10, Vol.372 (9647), p.1394-1402

2008

Volltextzugriff (PDF)

Abstract #1305594: Real-Life Effectiveness and Care Patterns of Diabetes Management in Eastern Europe, Middle East, and Africa (RECAP-DM EEMEA STUDY)

Endocrine practice, 2022-12, Vol.28 (12), p.S14-S14

2022

Volltextzugriff (PDF)

The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR

Diabetes therapy, 2023-10, Vol.14 (10), p.1609-1625

2023

Volltextzugriff (PDF)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes : editorial

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2012-01, Vol.17 (1), p.61-62

Amod, Aslam

2012

Volltextzugriff (PDF)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program

Indian journal of endocrinology and metabolism, 2022-03, Vol.26 (Suppl 1), p.S47-S48

2022

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)
Buchkapitel
(1)

Sprache

Englisch
(48)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Diabetes
(20)
Endocrinology & Metabolism
(17)
Humans
(16)
Diabetes Mellitus, Type 2 - Complications
(11)
Female
(10)
Glomerular Filtration Rate
(10)
Male
(10)
Patients
(10)
Type 2 Diabetes
(10)
Diabetes Mellitus
(9)
Double-Blind Method
(9)
Drug Therapy
(9)
Internal Medicine
(9)
Middle Aged
(9)
Cardiology
(8)
Diabetes Mellitus, Type 2 - Drug Therapy
(8)
Endocrinology
(8)
Aged
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial

Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives

The Place of Sulfonylureas in Guidelines: Why Are There Differences?

Introduction: Real-World Evidence in Type 2 Diabetes

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

Abstract #1305594: Real-Life Effectiveness and Care Patterns of Diabetes Management in Eastern Europe, Middle East, and Africa (RECAP-DM EEMEA STUDY)

The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes : editorial

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program

Suchergebnisse filtern